GDC-0980 Apitolisib

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：GDC-0980 Apitolisib	Purity：98% min
CAS NO：1032754-93-0	Solubility：DMSO : 14.29 mg/mL (28.66 mM)
Molecular Formula：C₂₃H₃₀N₈O₃S	Package：Package according to customer requirements
Molecular Weight：498.601	Storage：Store at -20℃

Quality control

Remarks

Apitolisib, also known as GDC-0980 and RG7422; or GNE390, is a dual PI3 kinase/mTOR inhibitor, is also a n orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor GDC-0980 inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR.

Related Products:

Everolimus; Temsirolimus; PI-103; Torin 1; PF-04691502; Torin 2; BGT226; Palomid 529; Deforolimus; KU-0063794; Rapamycin; Tacrolimus; LY294002

References

[1]. Sutherlin DP, et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem, 2011, 54(21), 7579-7587.

[2]. Wallin JJ, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther, 2011, 10(12), 2426-2436.